English

The exercise period for warrants of series TO 1 begins today

Report this content

Today, 18 August 2022, marks the beginning of the exercise period for warrants of series TO 1, that were issued in connection with CS MEDICA A/S’s (“CS MEDICA” or the “Company”) issue of units that took place in September 2021. The exercise period runs until and including 1 September 2022. Upon full exercise of warrants of series TO 1, CS MEDICA will receive approx. DKK 10.8 million before deduction of transaction related costs. An information document and subscription forms are available on the websites of CS MEDICA (www.cs-medica.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

Warrants of series TO 1
In September 2021, CS MEDICA carried out an issue of units (shares and attached free of charge warrants) in connection to its listing on Spotlight Stock Market. A total of 1,160,800 warrants of series TO 1 were issued.

During the exercise period, from 18 August 2022 to 1 September 2022, warrant holders have the possibility to, for each (1) warrant, subscribe for one (1) new share in CS MEDICA at a price of DKK 9.30 per share. Warrants of series TO 1 are traded on Spotlight Stock Market until 30 August 2022 but can be exercised until the last day in the exercise period, 1 September 2022. Thereafter the warrants will expire. Warrant holders are advised to contact their bank/nominee early on in the exercise period, as different time limits for subscription may apply. Upon full exercise of all warrants of series TO 1, CS MEDICA will be provided proceeds of approx. DKK 10.8 million before deduction of transaction related costs of approx. DKK 0.83 million.

The proceeds from the warrant exercise are intended to finance planned research and development, activities related to medical device regulation, global patents on upcoming treatment products, market penetration activities such as product launching, and clinical trials according to FDA guidance.

An information document and subscription forms are available on the websites of CS MEDICA (www.cs-medica.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

Important dates

  • 18 August 2022: Exercise period begins.
  • 30 August 2022: Last day of trading in warrants.
  • 1 September 2022: Exercise period ends.
  • 6 September 2022: Planned date for publication of the outcome of the warrant exercise.
  • 14 September 2022: Planned date for conversion from interim shares to shares.

The offer in brief

  • Exercise period: 18 August – 1 September 2022.
  • Exercise price: One (1) warrant gives the right to subscribe for one (1) new share at a price of DKK 9.30 per share.
  • Number of outstanding shares: 11,002,000.
  • Issue volume: If all warrants are exercised, the Company will receive approx. DKK 10.8 million before deduction of transaction related costs.
  • Ticker, ISIN: CSMED TO 1, DK0061668308.

Shares and share capital
Upon full exercise of warrants of series TO 1, the number of shares in CS MEDICA will increase by 1,160,800 shares, from 11,002,000 shares to 12,162,800.00 shares and the share capital will increase by DKK 75.452, from DKK 715.130 to DKK 790.582. Warrant holders who choose not to exercise their warrants of series TO 1 will be subject to a dilution effect corresponding to approximately 9.5 percent, calculated on the number of outstanding shares in CS MEDICA after full exercise of all warrants of series TO 1.

Advisors and issuing agent
Sedermera Corporate Finance AB is the financial advisor and Markets & Corporate Law Nordic AB is the legal advisor to CS MEDICA in connection with the warrant exercise. Nordic Issuing AB is the issuing agent.

For further information about the exercise of warrants, please contact:
Sedermera Corporate Finance AB
Phone: +46 40 - 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

Nordic Issuing AB
Phone: +46 (0)40-632 00 20
E-mail: info@nordic-issuing.se
www.nordic-issuing.se

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.

Tags:

warrants exercise TO1 CS MEDICA

Subscribe

Documents & Links